Kailera Therapeutics, Inc.
Every calculator, already run for KLRA
Open the full toolkit →You have the numbers on KLRA. Get the argument.
A written report on which of these readings actually decide the outcome for Kailera Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering KLRAAnalyst Price Target Disagreement for Kailera Therapeutics, Inc.
Wall Street's bull case implies +270% from the current price; the bear case implies +95%. A 175% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for KLRA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and inj…
KLRA — frequently asked
Is KLRA a buy right now?
Wall Street's consensus rating on Kailera Therapeutics, Inc. is none across 6 analysts, with a mean price target of $42.40 (+175% vs. the current $15.40). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is KLRA's next earnings date?
Kailera Therapeutics, Inc. is next scheduled to report earnings around Oct 29, 2026. A full KLRA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Kailera Therapeutics, Inc.?
Analysts covering Kailera Therapeutics, Inc. (KLRA) range from a bear-case target of $30.00 to a bull-case high of $57.00, with a mean consensus target of $42.40 across 5 analysts. The spread of $27.00 (175% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Kailera Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Kailera Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KLRA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Kailera Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.